News on Irinotecan_Hydrochloride from BioPortfolio.com http://www.BioPortfolio.com Consolidated Irinotecan_Hydrochloride news from BioPortfolio.com Wed, 10 Feb 2010 10:18:23 GMT en ArQule initiates two cancer studieshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030344&HITNO=0&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030344&THISHREF=http://c.moreover.com/click/here.pl%3fz2533577553%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030344&HITNO=0&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030344&THISHREF=http://c.moreover.com/click/here.pl%3fz2533577553%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comDatamonitor: ArQule Announces Initiation Of Clinical Programs With ARQ 197 In Germ Cell Tumors And Colorectal Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4026573&HITNO=1&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4026573&THISHREF=http://c.moreover.com/click/here.pl%3fz2530978589%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4026573&HITNO=1&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4026573&THISHREF=http://c.moreover.com/click/here.pl%3fz2530978589%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedical News Today: ArQule initiates two cancer studieshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4023928&HITNO=2&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4023928&THISHREF=http://c.moreover.com/click/here.pl%3fz2528489678%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4023928&HITNO=2&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4023928&THISHREF=http://c.moreover.com/click/here.pl%3fz2528489678%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-040http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4025325&HITNO=3&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4025325&THISHREF=http://c.moreover.com/click/here.pl%3fz2529669943%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4025325&HITNO=3&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4025325&THISHREF=http://c.moreover.com/click/here.pl%3fz2529669943%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmaceuticalProcessing: Keryx signs agreement with FDA for Phase III colorectal cancer trialhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024473&HITNO=4&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024473&THISHREF=http://c.moreover.com/click/here.pl%3fz2528912559%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024473&HITNO=4&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024473&THISHREF=http://c.moreover.com/click/here.pl%3fz2528912559%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comDatamonitor: AEterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Phttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022776&HITNO=5&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022776&THISHREF=http://c.moreover.com/click/here.pl%3fz2527853710%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022776&HITNO=5&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022776&THISHREF=http://c.moreover.com/click/here.pl%3fz2527853710%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimenshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4019556&HITNO=6&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4019556&THISHREF=http://c.moreover.com/click/here.pl%3fz2526367865%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4019556&HITNO=6&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4019556&THISHREF=http://c.moreover.com/click/here.pl%3fz2526367865%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMDLinx: ArQule Announces Initiation of Clinical Programs with ARQ 197 in Germ Cell Tumors and Colorectal Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4018207&HITNO=7&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4018207&THISHREF=http://c.moreover.com/click/here.pl%3fz2525525471%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4018207&HITNO=7&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4018207&THISHREF=http://c.moreover.com/click/here.pl%3fz2525525471%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: ArQule Announces Initiation of Clinical Programs with ARQ 197 in Germ Cell Tumors and Colorectal Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4018057&HITNO=8&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4018057&THISHREF=http://c.moreover.com/click/here.pl%3fz2525450740%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4018057&HITNO=8&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4018057&THISHREF=http://c.moreover.com/click/here.pl%3fz2525450740%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: ArQule Announces Initiation of Clinical Programs with ARQ 197 in Germ Cell Tumors and Colorectal Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4016734&HITNO=9&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4016734&THISHREF=http://c.moreover.com/click/here.pl%3fz2524861007%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4016734&HITNO=9&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4016734&THISHREF=http://c.moreover.com/click/here.pl%3fz2524861007%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: terna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial ohttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4015479&HITNO=10&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4015479&THISHREF=http://c.moreover.com/click/here.pl%3fz2524422810%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4015479&HITNO=10&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4015479&THISHREF=http://c.moreover.com/click/here.pl%3fz2524422810%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMontana's News Station: AEterna Zentaris says Keryx reaches SPA agreement with FDA for Phase III study of perifosinehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4015057&HITNO=11&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4015057&THISHREF=http://c.moreover.com/click/here.pl%3fz2524251758%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4015057&HITNO=11&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4015057&THISHREF=http://c.moreover.com/click/here.pl%3fz2524251758%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: AEterna Zentaris says Keryx reaches SPA agreement with FDA for Phase III study of perifosinehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014980&HITNO=12&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014980&THISHREF=http://c.moreover.com/click/here.pl%3fz2524231218%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014980&HITNO=12&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014980&THISHREF=http://c.moreover.com/click/here.pl%3fz2524231218%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: ArQule Announces Initiation of Clinical Programs with ARQ 197 in Germ Cell Tumors and Colorectal Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014948&HITNO=13&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014948&THISHREF=http://c.moreover.com/click/here.pl%3fz2524221568%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014948&HITNO=13&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014948&THISHREF=http://c.moreover.com/click/here.pl%3fz2524221568%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSmartBrief: Keryx signs agreement with FDA for Phase III colorectal cancer tr...http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014324&HITNO=14&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014324&THISHREF=http://c.moreover.com/click/here.pl%3fz2523966999%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014324&HITNO=14&MSIZE=117&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Irinotecan_Hydrochloride&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014324&THISHREF=http://c.moreover.com/click/here.pl%3fz2523966999%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comZibb: